文献速递心血管技术与安全CT

他汀降低非阻塞性冠心病患者心肌梗死与全因死亡风险

Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD.
PubMed 文献 · JACC Cardiovasc Imaging · 2021-07-14

本研究纳入丹麦西部2008至2017年因疑似冠心病行冠状动脉CTA显示狭窄<50%的33,552例患者,中位随访3.5年。结果显示心梗或全因死亡绝对风险随CAD负荷(CACS分级)递增,他汀治疗与各CAD负荷组心梗和死亡风险降低相关,且绝对获益随CAD负荷增加而增大。

要点

  • 非阻塞性CAD患者心梗/死亡风险随CACS分级递增,CACS≥400组事件率最高。
  • 他汀治疗在各CAD负荷组均与心梗和死亡风险降低相关(调整HR 0.44-0.52)。
  • 预防一例终点事件的NNT随CAD负荷增加而减小,重度组仅需13例。

诊断标准与关键数值

  • 无CAD组事件率4.13/1000患者年(95%CI 3.69-4.61)。
  • 轻度非阻塞性CAD(CACS 0-99)事件率7.74/1000患者年(95%CI 6.88-8.71)。
  • 中度非阻塞性CAD(CACS 100-399)事件率13.72/1000患者年(95%CI 11.61-16.23)。
  • 重度非阻塞性CAD(CACS≥400)事件率32.47/1000患者年(95%CI 26.25-40.16)。
  • 他汀治疗与心梗和死亡的调整HR:无CAD 0.52(95%CI 0.36-0.75),轻度0.44(95%CI 0.32-0.62),中度0.51(95%CI 0.34-0.75),重度0.52(95%CI 0.32-0.86)。

临床应用与阅片要点

  • 冠状动脉CTA报告应描述非阻塞性CAD的负荷(如CACS分级),以提示预后风险。
  • 对无阻塞性CAD但CACS≥400的患者,应提示临床考虑他汀治疗以降低心梗和死亡风险。
  • 他汀的绝对获益随CAD负荷增加而增大,重度非阻塞性CAD患者NNT更低。

局限性

  • 残余混杂可能持续存在,但不能完全解释观察到的他汀相关风险降低。
  • 研究为观察性设计,非随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this work was to evaluate the prognostic impact of statin therapy in symptomatic patients without obstructive CAD.

BACKGROUND: Information on the prognostic impact of post-coronary computed tomographic angiography (CTA) statin use in patients with no or nonobstructive coronary artery disease (CAD) is sparse.

METHODS: Patients undergoing CTA with suspected CAD in western Denmark from 2008 to 2017 with <50% coronary stenoses were identified. Information on post-CTA use of statin therapy and cardiovascular events were obtained from national registries.

RESULTS: The study included 33,552 patients, median aged 56 years, 58% female, with no (n = 19,669) or nonobstructive (n = 13,883) CAD and a median follow-up of 3.5 years. The absolute risk of the combined end point of myocardial infarction (MI) or all-cause mortality was directly associated with the CAD burden with an event rate/1,000 patient-years of 4.13 (95% CI: 3.69-4.61) in no, 7.74 (95% CI: 6.88-8.71) in mild (coronary artery calcium score [CACS] 0-99), 13.72 (95% CI: 11.61-16.23) in moderate (CACS 100-399), and 32.47 (95% CI: 26.25-40.16) in severe (CACS ≥400) nonobstructive CAD. Statin therapy was associated with a multivariable adjusted HR for MI and death of 0.52 (95% CI: 0.36-0.75) in no, 0.44 (95% CI: 0.32-0.62) in mild, 0.51 (95% CI: 0.34-0.75) in moderate, and 0.52 (95% CI: 0.32-0.86) in severe nonobstructive CAD. The estimated numbers needed to treat to prevent the primary end point were 92 (95% CI: 61-182) in no, 36 (95% CI: 26-58) in mild, 24 (95% CI: 15-61) in moderate, and 13 (95% CI: 7-86) in severe nonobstructive CAD. Residual confounding may persist, but not to an extent explaining all of the observed risk reduction associated with statin treatment.

CONCLUSIONS: The risk of MI and all-cause mortality in patients without obstructive CAD is directly associated with the CAD burden. Statin therapy is associated with a reduction of MI and all-cause death across the spectrum of CAD, however, the absolute benefit of treatment is directionally proportional with the CAD burden.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Øvrehus KA, Diederichsen A, Grove EL, et al. Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD. JACC Cardiovasc Imaging. 2021. PMID: 34274285. doi:10.1016/j.jcmg.2021.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。